Sanofi ADS (SNY)
NASDAQ: SNYHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SNY stock chart
Technical analysisKey statistics
All statistics- Market cap
- $111.70B
- P/E (TTM)
- 23.14
- Forward P/E
- 8.57
- EPS (TTM)
- $2.01
- Dividend yield
- 5.20% ($0.00)
- Ex-dividend date
- May 4, 2026
- 52-week range
- 39.07 – 50.61
- Day range
- 46.45 – 46.98
- Volume / Avg
- 4.29M / 3.41M
- Beta
- —
- Shares outstanding
- 2.40B
- Next earnings
- Jan 28, 2027
52-week range
SNY stock today
On Nov 20, SNY ended the session at $46.52, adding $0.46 (1.00%), versus the S&P 500's 3.70% decline. At this level, SNY sits in the middle of its 52-week range of $39.07 to $50.61: 8.1% below the high, set on Nov 25, 2025 and 19.1% above the low. SNY is down 4.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 6.3%.
At 23.1x trailing earnings, Sanofi trades above the peer-group median of 20.4x. Its forward P/E of 8.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Sanofi's next earnings report is expected on Jan 28, 2027.
Summary generated from market data by MetaCap's automated system. Methodology
About Sanofi
Company profileSanofi engages in the research, development, manufacture, and marketing of therapeutic solutions in Finland and Germany. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection; hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines; and Fluzone, a flu vaccine.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Ms. Belen Garijo Lopez M.D.
- Headquarters
- Paris
- Employees
- 74,846
- Website
- sanofi.com
Analyst forecast
ForecastConsensus (11 analysts)
buy
Avg. price target
$54.92+18.06%
- Strong buy 2
- Buy 4
- Hold 5
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Jan 28, 2027
- Last reported (Sep/2026)
- Oct 30, 2026
- EPS actual vs est.
- $1.70 vs $1.63
- Surprise
- +4.29%
Dividends
Dividend history- Annual dividend
- $0.00
- Dividend yield
- 5.20%
- Last payment
- $2.42
- Ex-dividend date
- May 4, 2026
SNY news
All SNY news- Sanofi Maps Vaccine Pipeline With Flu-COVID and Pneumococcal Trial Results AheadNasdaq
- Sanofi's Next-Generation Rabies Vaccine Secures Approval in EUNasdaqSNY, ADPT, ACIU, AMRX
- SNY Wins FDA Approval for Infilbray in Type 3 Gaucher DiseaseNasdaqSNY, ADPT, ACIU, AMRX
- Sanofi's VaxRabeo Approved In Europe For Rabies Prevention Across All GroupsNasdaq
- Sanofi Wins First U.S. Approval For Infilbray Type 3 Gaucher DiseaseNasdaq
- Sanofi Wins First U.S. Approval For Neurological Symptoms Of Type 3 Gaucher DiseaseNasdaq
- FDA Approves Sanofi's Infilbray To Treat Neurological Symptoms Of Type 3 Gaucher DiseaseNasdaq
- Regeneron Wins EC Clearance for Libtayo Dosing FlexibilityNasdaqREGN, SNY, CTMX
Sanofi peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BMYBristol-Myers Squibb Company | 58.80 | +0.79% | $120.19B | vs SNY |
| GSKGSK plc ADR | 47.76 | -0.13% | $95.73B | vs SNY |
| REGNRegeneron Pharmaceuticals Inc. | 920.69 | -0.19% | $95.24B | vs SNY |
| VRTXVertex Pharmaceuticals Incorporated | 515.02 | -1.08% | $130.58B | vs SNY |
| TAKTakeda Pharmaceutical Company Limited ADR | 21.77 | +1.68% | $69.55B | vs SNY |
| PFEPfizer Inc. | 27.40 | -0.51% | $156.18B | vs SNY |
| NVONovo Nordisk A/S | 37.82 | -2.70% | $166.69B | vs SNY |
| ABTAbbott Laboratories | 103.00 | -0.84% | $178.39B | vs SNY |
Indexes, lists and sector
Sanofi stock FAQ
What is Sanofi's stock price today?
SNY last traded at $46.52 as of Nov 20, 4:00 PM EST, up 1.00% on the day. Prices are delayed at least 15 minutes.
Does Sanofi pay a dividend?
Yes. Sanofi pays $0.00 per share annually, a 5.20% yield. The most recent dividend of $2.42 had an ex-dividend date of May 4, 2026.
When is Sanofi's next earnings date?
Sanofi is expected to report earnings on Thursday, January 28, 2027.
What is SNY's P/E ratio?
SNY trades at a trailing P/E ratio of 23.14 and a forward P/E of 8.57, compared with a median of 20.4 for its closest peers.
Who is Sanofi's CEO?
Ms. Belen Garijo Lopez M.D. is the chief executive officer of Sanofi ADS, which has about 74,846 employees.
What is the SNY 52-week high?
The 52-week high for SNY is $50.61 and the 52-week low is $39.07. The stock is currently 8.1% below its high.